1.13
-0.02 (-1.74%)
| Previous Close | 1.15 |
| Open | 1.14 |
| Volume | 6,014,250 |
| Avg. Volume (3M) | 22,340,677 |
| Market Cap | 211,306,608 |
| Price / Sales | 195.00 |
| 52 Weeks Range | |
| Earnings Date | 14 Aug 2026 |
| Diluted EPS (TTM) | 4.09 |
| Current Ratio (MRQ) | 0.720 |
| Operating Cash Flow (TTM) | -64.05 M |
| Levered Free Cash Flow (TTM) | -35.91 M |
| Return on Assets (TTM) | -122.34% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Outlook Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | 1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.25 |
|
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 38.31% |
| % Held by Institutions | 16.89% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Gilpin Wealth Management, Llc | 30 Jun 2026 | 555,000 |
| Nine Masts Capital Ltd | 31 Mar 2026 | 232,546 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |